Pain Therapeutics, Inc. Share Price Nasdaq
Equities
US69562K5065
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 300M 25.01B | Capitalization | 966M 80.55B |
---|---|---|---|---|---|
Net income 2024 * | -92M -7.67B | Net income 2025 * | 120M 10.01B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.22 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
13.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.82% |
Managers | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01/98/01 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 01/18/01 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 04/21/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01/98/01 |
Robert Gussin
BRD | Director/Board Member | 86 | 01/03/01 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07/07/07 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |